Abstract: Prostate cancer (PCa) is one of the most common malignant tumors in men. Early diagnosis and accurate staging are of great significance for formulating treatment plans and improving patient prognosis. As a key target for PCa diagnosis, researches in prostate specific membrane antigen (PSMA) have achieved significant advances in PCa-related fields in recent years. The authors review the diagnostic efficacy and clinical application value of PSMA-based radionuclide-labeled probes, discuss the advantages and limitations of various probes, and aim to provide a reference for the clinical application of PSMA-targeted imaging technology in the precise diagnosis of PCa.